Literature DB >> 15800145

Critical periods of suicide risk in Huntington's disease.

Jane S Paulsen1, Karin Ferneyhough Hoth, Carissa Nehl, Laura Stierman.   

Abstract

Contrary to popular belief, receiving a diagnosis of a devastating fatal disease does not exacerbate, and may even alleviate, the risk of suicide. Suicidal ideation was examined in 4,171 individuals in the Huntington Study Group database. Participants were grouped according to a standardized neurological examination from 0 (i.e., normal examination) to 3 (definite Huntington's disease). Patients with an unequivocal diagnosis of Huntington's disease were further divided by stage of disease, from stage 1 (early) to stage 5 (end stage). Findings showed that the frequency of suicidal ideation doubled from 9.1% in at-risk persons with a normal neurological examination to 19.8% in at-risk persons with soft neurological signs and increased to 23.5% in persons with "possible Huntington's disease." In persons with a diagnosis of Huntington's disease, 16.7% had suicidal ideation in stage 1, and 21.6% had suicidal ideation in stage 2, whereas the proportion of Huntington's disease patients with suicidal ideation diminished thereafter. Findings suggest two critical periods for increased risk of suicide in Huntington's disease. The first critical period is immediately before receiving a formal diagnosis of Huntington's disease, and the second is in stage 2 of the disease, when independence diminishes. Although the underlying mechanisms of suicidal ideation in Huntington's disease are poorly understood, it is critical for health care providers to be aware of periods during which patients may be at an increased risk.

Entities:  

Mesh:

Year:  2005        PMID: 15800145     DOI: 10.1176/appi.ajp.162.4.725

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  35 in total

1.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  The right to ignore genetic status of late onset genetic disease in the genomic era; Prenatal testing for Huntington disease as a paradigm.

Authors:  A Erez; K Plunkett; V R Sutton; A L McGuire
Journal:  Am J Med Genet A       Date:  2010-07       Impact factor: 2.802

3.  Challenges assessing clinical endpoints in early Huntington disease.

Authors:  Jane S Paulsen; Chiachi Wang; Kevin Duff; Roger Barker; Martha Nance; Leigh Beglinger; David Moser; Janet K Williams; Sheila Simpson; Douglas Langbehn; Daniel P van Kammen
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

4.  Neural bases of dysphoria in early Huntington's disease.

Authors:  Sergio Paradiso; Beth M Turner; Jane S Paulsen; Ricardo Jorge; Laura L Boles Ponto; Robert G Robinson
Journal:  Psychiatry Res       Date:  2008-01-15       Impact factor: 3.222

Review 5.  "Pre-symptomatic" Huntington's disease.

Authors:  Kevin Duff; Leigh J Beglinger; Jane S Paulsen
Journal:  Handb Clin Neurol       Date:  2008

6.  An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers.

Authors:  Anthony L Vaccarino; Karen Anderson; Beth Borowsky; Kevin Duff; Joseph Giuliano; Mark Guttman; Aileen K Ho; Michael Orth; Jane S Paulsen; Terrence Sills; Daniel P van Kammen; Kenneth R Evans
Journal:  Mov Disord       Date:  2011-03-02       Impact factor: 10.338

7.  Suicidal ideation in Huntington disease: the role of comorbidity.

Authors:  Heather H Wetzel; Carissa R Gehl; Lisa Dellefave-Castillo; Judith F Schiffman; Kathleen M Shannon; Jane S Paulsen
Journal:  Psychiatry Res       Date:  2011-05-24       Impact factor: 3.222

8.  Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.

Authors:  Samuel Frank
Journal:  BMC Neurol       Date:  2009-12-18       Impact factor: 2.474

9.  Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.

Authors:  Melissa J Armstrong; Janis M Miyasaki
Journal:  Neurology       Date:  2012-07-18       Impact factor: 9.910

10.  Depressive-like behavior in mice recently recovered from motor disorders after 3-nitropropionic acid intoxication.

Authors:  Xiao-Min Li; Bing-Gen Zhu; Sha Ma; Wei Zhou; Zheng Wei; Yu-Xiang Zheng; Xu-Dong Zhao; Rong-Shen Zhu
Journal:  Neurosci Bull       Date:  2008-08       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.